Mastering GLP-1 Agonists
Want free CE credit? You’re getting an exclusive look at one of our Pinnacle Education Membership videos—no subscription needed. Just watch the video above, then click the link below to claim your CE credit!
In “Mastering GLP-1 Agonists,” Dr. Alexandra Sowa, a board-certified internist and obesity medicine specialist, provides an in-depth exploration of GLP-1 receptor agonists as a therapeutic tool in the management of obesity and Type 2 diabetes. Through this recorded Q&A, Dr. Sowa answers practical questions about GLP-1 mechanisms of action, patient eligibility, dosing strategies, and management of common side effects. She also highlights evidence-based outcomes for weight loss and metabolic health improvements. This engaging session is designed to clarify misconceptions and address real-world challenges, empowering healthcare professionals to optimize treatment outcomes for their patients.
More about Dr. Alexandra Sowa
Dr. Alexandra Sowa is a board-certified physician of Internal Medicine, specializing in preventive health, nutrition and obesity medicine. She is a diplomate of the American Board of Obesity Medicine. After graduating with honors from Johns Hopkins University, Dr. Sowa attended New York University School of Medicine, where she completed both medical school and a residency in Internal Medicine. Alexandra currently practices in New York City and holds an appointment as Clinical Instructor in Medicine at New York University School of Medicine. She is honored to have been named 1 of 4 ‘Rising Star’ Super Doctors in New York City for Internal Medicine in 2017, 2018 and 2019. She has also served as an on-air health expert for national media outlets like Fox News, CBS News, NPR and Inside Edition. Her medical opinions have been featured in various print publications, from the New York Times to U.S. News and World Report to Glamour and Parents Magazine.
Disclosures
All of the relevant financial relationships of individuals for this activity have been mitigated.
Statement Of Need
The increasing prevalence of obesity, Type 2 diabetes, and related metabolic conditions highlights a critical need for healthcare professionals to stay updated on effective, evidence-based treatment options. GLP-1 receptor agonists have emerged as a leading therapy due to their ability to improve glycemic control, promote weight loss, and reduce cardiovascular risk. However, many clinicians face challenges in understanding the mechanisms, patient selection criteria, dosing protocols, and side effect management for GLP-1 agonists. This Q&A session addresses these gaps by equipping providers with the knowledge and confidence to incorporate GLP-1 agonists into clinical practice effectively.
Objectives
Explain the mechanism of action of GLP-1 receptor agonists and their physiological effects on glycemic control and weight loss.
Identify appropriate patient populations for the use of GLP-1 receptor agonists in managing obesity and Type 2 diabetes.
Discuss practical dosing strategies, including initiation, titration, and monitoring for efficacy and safety.
Evaluate the latest clinical evidence supporting the use of GLP-1 agonists for improving metabolic health and reducing cardiovascular risk.
